Ignite Creation Date:
2025-12-24 @ 9:32 PM
Ignite Modification Date:
2026-03-14 @ 9:06 AM
Study NCT ID:
NCT03388632
Status:
COMPLETED
Last Update Posted:
2025-12-18
First Post:
2017-12-30
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers
Sponsor:
National Cancer Institute (NCI)
Organization:
Organization Data
Organization:
Class:
NIH
Study ID:
180033
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
NIH
Responsible Party:
Responsible Party Title:
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None